Preview

Medical Immunology (Russia)

Advanced search

ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN

https://doi.org/10.15789/1563-0625-2017-2-157-164

Abstract

So far, there is no effective treatment for a number of socially significant bacterial and fungal diseases. β-(1→3) glucans are polysaccharides consisting of glucose units linked together with β-(1→3)- glycoside bonds. They are principal components of the fungal cell wall including such dangerous nosocomial pathogens as Candida albicans, Aspergillus fumigatus and others. At the same time, β-(1→3) glucans are absent in humans and other mammals, thus making them to be promising components of carbohydrate-protein conjugate vaccines for prevention and treatment of fungal infections. The CRM197 protein is a non-toxic derivative of diphtheria toxin, which is widely used as a safe carrier for conjugate vaccines. The CRM197 extraction from lysogenic C. diphtheriae cultures is a classic way of its production. An alternative to the classic method is a transgene-driven CRM197 protein expression in E. coli, B. subtilis and Pseudomonas fluorescens. The advantage for using Escherichia coli in this case is that this method is more simple and inexpensive, and allows of producing recombinant CRM197 within short terms employing a non-pathogenic microorganism. The purpose of this study was to investigate antigenic activity in the samples of experimental conjugate vaccines based on synthetic oligosaccharide ligands and CRM197 carrier protein, by means of a competitive ELISA. A double immunization of laboratory Balb/c mice with experimental samples of conjugate vaccines based on oligosaccharide ligands and CRM197 protein caused induction of specific antibodies at high titers. All the samples of oligoglucoside-based conjugate vaccines with different contents of monomeric units (pentasaccharides, heptasaccharides, nanosaccharides, and undecasaccharides) caused the formation high antibody titer at the level 1: 51,200,following tandem injections. High avidity of antibodies to their oligosaccharide ligands was shown by competitive ELISA reaction. These data suggest a relevance of further pre-clinical trials of conjugate vaccines against Candida and Aspergillus, as well as selection of the most immunogenic and effective version of the conjugate vaccine.

 

About the Authors

E. G. Bogomolova
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
Junior Research Associate, Laboratory of Genetically Engineered Vaccines


O. A. Dodrovolskaya
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
Junior Research Associate, Laboratory of Genetically Engineered Vaccines


E. A. Fedorova
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
Research Associate, Laboratory of Genetically Engineered Vaccines


A. M. Kondrashkina
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
Senior Laboratory Assistant, Laboratory of Genetically Engineered Vaccines


N. N. Kolmakov
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
Senior Research Associate, Laboratory of Genetically Engineered Vaccines


S. A. Ishchuk
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
First Rank Engineer, Laboratory of Genetically Engineered Vaccines


I. V. Dukhovlinov
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg
Russian Federation
PhD (Biology), Chief, Laboratory of Genetically Engineered Vaccines


A. S. Simbirtsev
Research Institute of Highly Pure Biopreparations, Russian Federal Agency for Medicine and Biology, St. Petersburg Pavlov First St. Petersburg State Medical University, St. Petersburg
Russian Federation
PhD, MD (Medicine), Professor, Director


References

1. Духовлинов И.В., Федорова Е.А., Богомолова Е.Г., Добровольская О.А., Черняева Е.Н., Аль-Шехадат Р.И., Симбирцев А.С. Получение рекомбинантного белка CRM197 в клетках E. coli. Инфекция и иммунитет. 2015. Т. 5, № 1. С. 37- 44. [Dukhovlinov I.V., Fedorova E.A., Bogomolova E.G., Dobrovolskaya O.A., Chernyaeva E.N., Al-Shekhadat R.I., Simbirtsev A.S. [Production of recombinant protein CRM197 in Escherihia coli. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2015, Vol. 5, no. 1, pp. 37-44. (in Russ.)]. http://dx.doi.org/10.15789/2220-7619-2015-1-37-44

2. Blanchard-Rohner, G. The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine, 2013, Vol. 31, no. 20, pp. 2441-2448.

3. CDC. Recommendations of the Immunization Practices Advisory Committee: prevention of pneumococcal pisease. MMWR, 1997, no. 46, p. 8.

4. Clements D.A., Gilbert G.L. Immunization for the prevention of Haemophilus influenzae type b infections: a review. Aust. N. Z. J. Med. 1990, no. 20, pp. 828-834.

5. Dagan R., Poolman J., Siegrist C.-A. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010, Vol. 28, no. 34, pp. 5513-5523.

6. Ito J.I. T cell immunity and vaccines against invasive fungal diseases. Immunological Investigations. 2011, Vol. 40, pp. 825-838.

7. Komarova B.S., Orekhova M.V., Tsvetkov Y.E., Beau R., Aimanianda V., Latgé J.P., Nifantiev N.E. Synthesis of a pentasaccharide and neoglycoconjugates related to fungal α-(1→3)-glucan and their use in the generation of antibodies to trace Aspergillus fumigatus cell wall. Chemistry. 2015, Vol. 21, no. 3, pp. 1029-1035.

8. Retallack D.M. Reliable protein production in a Pseudomonas fluorescens expression system. Protein Expr. Purif. 2012, Vol. 81, no. 2, pp. 157-165.

9. Van den Biggelaar A.H.J. et al. Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance. Vaccine, 2011, Vol. 29, no. 33, pp. 5414-5420.

10. Wang X.J., Sui X., Yan L., Wang Y., Cao Y.B., Jiang Y.V. Vaccines in the treatment of invasive candidiasis. Virulence, 2015, Vol. 6, no. 4, pp. 309-315.

11. Yashunsky D.V.,Tsvetkov Y.E., Grachev A.A., Chizhov A.O., Nifantiev N.E. Synthesis of 3-aminopropyl glycosides of linear β-(1→3)-D-glucooligosac-charides. Carbohydrate Research, 2016, Vol. 419, no. 8, p. 17.

12. Zhou J. Secretory expression of recombinant diphtheria toxin mutants in B. Subtilis. J. Tongji Med. Univ. Tong Ji Yi Ke Xue Xue Bao, 1999, Vol. 19, no. 4, pp. 253-256.


Review

For citations:


Bogomolova E.G., Dodrovolskaya O.A., Fedorova E.A., Kondrashkina A.M., Kolmakov N.N., Ishchuk S.A., Dukhovlinov I.V., Simbirtsev A.S. ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN. Medical Immunology (Russia). 2017;19(2):157-164. (In Russ.) https://doi.org/10.15789/1563-0625-2017-2-157-164

Views: 4491


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)